Press release from Boule Diagnostics AB's Annual General Meeting on April 23, 2013

At the 2013 Annual General Meeting, the balance sheets and income statements for the Parent Company and Group were adopted for the 2012 fiscal year. The Annual General Meeting resolved to pay a dividend of SEK 0.50 per share for 2012 and that the remaining profits be carried forward.

The Meeting discharged the Board members and President from liability for the 2012 fiscal year.

The Meeting approved the Nomination Committee’s proposal that the Board of Directors comprise five members, with no deputy members.

The Meeting resolved to pay Board fees according to the following: SEK 300,000 (300,000 for 2012) to the Chairman and SEK 150,000 (150,000 for 2012) to each of the remaining Board members. The amount of Board fees to be paid will thus total SEK 900,000 (900,000 for 2012). The Meeting also resolved to reserve SEK 35,000 (35,000 for 2012) to be distributed by the Chairman for committee work as applicable. If the Chairman of the Board is a member of a committee, he is entitled to the same fees as the other members of the committee. On condition that it is permissible according to tax law and cost-neutral for the company, Board members are entitled to invoice Board fees (as well as the associated social security fees and VAT) through companies owned by Board members. It was also resolved that fees to auditors will be paid according to continuous invoicing, as in the past.

The Annual General Meeting resolved to re-elect Lars-Olof Gustavsson, Britta Dalunde, Eva-Lotta Kraft, Åke Nygren and Gösta Oscarsson as Board members for the period until the end of the next Annual General Meeting. Lars-Olof Gustavsson was re-elected Chairman of the Board.

The Meeting approved the proposed instructions for the Nomination Committee.

The Meeting approved the Board of Directors’ motion for guidelines for remuneration of senior executives.

The Meeting approved the Board’s motion concerning an incentive program for 2013/2017.

The Meeting approved the Board’s motion concerning authorization to increase the share capital through new issues of shares, warrants and/or convertibles.
Complete motions pertaining to the Annual General Meeting’s resolutions above are available on Boule’s website,

For further information, please contact:
Lars-Olof Gustavsson, Chairman of the Board of Boule Diagnostics AB, tel: +46 8 14 54 20
Ernst Westman, President and CEO of Boule Diagnostics AB, tel: +46 708 60 88 63

The information in this press release is such that Boule Diagnostics AB is obligated to publish in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 24, 2013 at 08:00 a.m.

About Boule Diagnostics AB

Boule Diagnostics AB is a rapidly growing diagnostic company that develops, manufactures and sells systems and consumer products for complete blood counts (hematology) to non-institutional healthcare. The company focuses primarily on small and midsize hospitals, clinics and laboratories in non-institutional healthcare, as well as other diagnostic companies in both human and veterinary hematology. Operations are conducted through commercial subsidiaries in Sweden, the US and China. The Boule Diagnostics share has been listed on NASDAQ OMX Stockholm since 2011.


  • Subscribe to our news